You need to granularly read each announcement for particulars.
2020-2022: The majority of the revenue (if not 99% of it) was down to Covidx / Viradx. Febridx did manage small sales in the UK early on.
2023: Solely international sales of product.
2024: Initial US orders for Viradx and international sales again.
Febridx has been minimal in revenue for the last 4 years. Viradx/Covidx has been the primary product revenue for this entire time.
However, this quarter was supposed to be the "robust start" to sales and it simple was no different to any other quarterly period previously, hence the table i pulled up. Not the commentary is rubbish as that is pulled from whatever commentary is generalised in the announcements. The figures are accurate however.
This from the 1HFY24 announcement, this chart has not really changed on how their revenue is made. They need to increase the Febridx sales outside the US as they know the US is some time away.
LDX Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)